Tiziana Life Sciences (TLSA) Prices 11M ADS Follow-Offering at $5.20/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Pre-Open Stock Movers 07/31: (PINS) (FB) (AAPL) (AMZN) Higher; (TEAM) (MOH) (RDFN) Lower (more...)
July 31, 2020 9:23 AM EDTPre-Open Stock Movers
electroCore, Inc. (Nasdaq: ECOR) 81.8% HIGHER; announced more information about availability, distribution and pricing for gammaCore Sapphire CV non-invasive vagus nerve stimulation (nVNS) therapy under its Emergency Use Authorization (EUA). The EUA allows for the use of gammaCore Sapphire CV at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief.
Tiziana Life Sciences plc... More
Tiziana Life Sciences (TLSA) Announces Submission of Patent Application for Nasal Administration of Foralumab for Treatment of COVID-19 Patients
July 31, 2020 6:24 AM EDTTiziana Life Sciences plc (Nasdaq: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), for the treatment of COVID-19 either alone or in combination with other anti-viral drugs. Recent clinical studies imply that a combination of anti-inflammatory and anti-viral drugs may be more effective to treat patients at different stages of COVID-19 disease.
Nasal administration with Foralumab could potentially... More
